Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1996-11-6
pubmed:abstractText
Forty-three patients with metastatic melanoma were treated with a 5 day (18 patients) and a 3 day (25 patients) schedule of high-dose IL-2 11.7 MIU m2 and IFN-alpha 3 MIU m2 i.v. by bolus administration every 8 h, repeated every 21 days for a total of three courses. The 5 day schedule resulted in a high response rate of 41% (CI 18-67%), but was accompanied by severe cardiotoxicity (41%) and central nervous system toxicity (28%). The 3 day schedule was associated with manageable toxicity, but yielded a moderate response rate of 20% (CI 7-43%).
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-1629914, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-1634924, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-1870152, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-2066760, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-2124246, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-2213101, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-2358835, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-2679456, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-2685181, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-3497595, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-7738617, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-7779731, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-8054006, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-8120958, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-8229131, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-8319195, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-8343275, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-8410122, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-8453558, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-8468720, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-8478661, http://linkedlifedata.com/resource/pubmed/commentcorrection/8826864-8567110
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
74
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
951-5
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
pubmed:affiliation
Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek, The Netherlands.
pubmed:publicationType
Journal Article